Mektovi Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Binimetinib

Indications/Uses

In combination w/ encorafenib in adult patients w/ unresectable or metastatic melanoma w/ BRAF V600E or V600K mutation as detected by a validated test.

Dosage/Direction for Use

Adult 45 mg bd approx 12 hr apart when used in combination w/ encorafenib. Dose modification: Individualized dosing. Recommended dose: 30 mg bd. Consider re-escalation to 45 mg bd if the AR that resulted in a dose reduction is under effective management. Reduce encorafenib to 300 mg once daily during temporary interruption of binimetinib.

Administration

May be taken with or without food: Swallow whole w/ water.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EE03 - binimetinib ; Belongs to the class of mitogen-activated protein kinase (MEK) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Mektovi FC tab 15 mg

Packing/Price

1's

Mektovi

Manufacturer:

ALMAC Pharma Services Limited